Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.
Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.
复制标题
DOI:
10.1093/infdis/jiw338
复制
发表时间:
2016-10-15
期刊:
影响因子:
--
通讯作者:
Parikh S
中科院分区:
文献类型:
--
作者:
Tchaparian E;Sambol NC;Arinaitwe E;McCormack SA;Bigira V;Wanzira H;Muhindo M;Creek DJ;Sukumar N;Blessborn D;Tappero JW;Kakuru A;Bergqvist Y;Aweeka FT;Parikh S
Background. The pharmacokinetics and pharmacodynamics of lumefantrine, a component of the most widely used treatment for malaria, artemether-lumefantrine, has not been adequately characterized in young children. Methods. Capillary whole-blood lumefantrine concentration and treatment outcomes were determined in 105 Ugandan children, ages 6 months to 2 years, who were treated for 249 episodes of Plasmodium falciparum malaria with artemether-lumefantrine. Results. Population pharmacokinetics for lumefantrine used a 2-compartment open model with first-order absorption. Age had a significant positive correlation with bioavailability in a model that included allometric scaling. Children not receiving trimethoprim-sulfamethoxazole with capillary whole blood concentrations <200 ng/mL had a 3-fold higher hazard of 28-day recurrent parasitemia, compared with those with concentrations >200 ng/mL (P = .0007). However, for children receiving trimethoprim-sulfamethoxazole, the risk of recurrent parasitemia did not differ significantly on the basis of this threshold. Day 3 concentrations were a stronger predictor of 28-day recurrence than day 7 concentrations. Conclusions. We demonstrate that age, in addition to weight, is a determinant of lumefantrine exposure, and in the absence of trimethoprim-sulfamethoxazole, lumefantrine exposure is a determinant of recurrent parasitemia. Exposure levels in children aged 6 months to 2 years was generally lower than levels published for older children and adults. Further refinement of artemether-lumefantrine dosing to improve exposure in infants and very young children may be warranted.
登录
查看更多内容
影响因子:
3
作者:
Staehli Hodel EM;Guidi M;Zanolari B;Mercier T;Duong S;Kabanywanyi AM;Ariey F;Buclin T;Beck HP;Decosterd LA;Olliaro P;Genton B;Csajka C
通讯作者:
Csajka C
DOI:
10.1016/s1473-3099(15)00487-9
发表时间:
2016-03
期刊:
The Lancet. Infectious diseases
影响因子:
--
作者:
Amaratunga C;Lim P;Suon S;Sreng S;Mao S;Sopha C;Sam B;Dek D;Try V;Amato R;Blessborn D;Song L;Tullo GS;Fay MP;Anderson JM;Tarning J;Fairhurst RM
通讯作者:
Fairhurst RM
影响因子:
3.3
作者:
Ashley, Elizabeth A.;Stepniewska, Kasia;Nosten, Francois
通讯作者:
Nosten, Francois
影响因子:
4.9
作者:
Kredo, T.;Mauff, K.;Barnes, K. I.
通讯作者:
Barnes, K. I.
影响因子:
3
作者:
Green, Michael;Otieno, Kephas;Desai, Meghna
通讯作者:
Desai, Meghna